The poor response of glioblastoma to current treatment protocols is a consequence of its
intrinsic drug resistance. Resistance to chemotherapy is primarily associated with …

Cancer stem cells (CSC) constitute a small area of the tumor mass and are characterized by
self-renewal, differentiation and the ability to promote the development of secondary chemo …

Background Glioblastoma (GBM) is a high-grade, poor prognosis tumor that is resistant to
standard treatment. The presence of a small number of glioma stem cells (GSCs) surviving …

Glioblastoma multiforme is the most aggressive and malignant primary brain tumour, with a
median survival rate of between 15 to 17 months. Heterogeneous regions occur in …

The present study aimed to construct and evaluate a novel experiment-based hypoxia
signature to help evaluations of GBM patient status. First, the 426 proteins, which were …

Background In high-grade chondrosarcoma, 5-year survival is lower than 50%. Therefore, it
is important that preclinical models that mimic the disease with the greatest possible fidelity …

Gliomas (GBM) are the most common and malignant form of brain tumors. Glioma cells are
largely resistant to available treatments including to the alkylating agent temozolomide …

Hypoxia is a powerful driver of the malignant phenotype in solid tumors including gliomas. A
major, though not sole, driver of this effect is the hypoxia-inducible factors (HIF) which …

Background: Glioblastoma (GBM) is a high-grade, poor prognosis tumor that is resistant to
standard treatment. The presence of a small number of glioma stem cells (GSCs) surviving …

Glioma is the most common and aggressive type of malignant brain tumors. High-grade
gliomas, including WHO grade III (anaplastic astrocytoma and oligodendroglioma) and WHO …